Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early

Executive Summary

Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.

You may also be interested in...



Data At ASCO From J&J Zytiga Trial’s Early End = Intel For Medivation’s MDV3100 Program

Details from the COU-302 trial of Johnson & Johnson’s Zytiga, stopped early for efficacy in March, were released at the American Society of Clinical Oncology meeting, revealing to Medivation/Astellas insights on how to tweak their ongoing registrational trial for enzalutamide (MDV3100) in the pre-chemo prostate cancer space.

Will China's Enlarged Medical Insurance System Cover More Oncology Treatments?

SHANGHAI - Although China's pharmaceutical market slowed down in the first quarter of 2011 due to price cuts and policy headwinds, it still grew at 14.5% compared to the same period last year, according to data from investment brokerage Citi. Growth largely was driven by increasing medical expenses in the world second largest economy, and in particular was fueled by China's second and third-tier cities, away from the coast, which saw first quarter prescription drug growth rates between 20-30% year over year

Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy

FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel